Zhejiang maker of vitamin D3 and its derivatives, a major global supplier to supplement and food industries.
Zhejiang maker of vitamin D3 and its derivatives, a major global supplier to supplement and food industries.
Makes vitamin D3 from lanolin, a wax recovered from sheep's wool, and sells it in bulk, so earnings follow D3 prices, which depend on how much the few big producers make. Its calcifediol line (25-hydroxy D3), used in animal feed, is a more specialised product that fetches a higher price per tonne.
In one line: A Chinese vitamin-D3 ingredient supplier.
Moat: narrow (scale, process know-how). One of the world's larger vitamin D3 producers with integrated extraction and synthesis capacity.
Headquarters: Shaoxing, Zhejiang, China · Employees: 1,163
Size Zhejiang Garden Biopharmaceutical (300401.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $922M, the 2314th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.54 on 18 Nov 2026.
Performance Over six months the shares fell 14.1%, against -20.9% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 2.4% over the last twelve months (peer median +11.3%); the operating margin is 23.6% (peer median 7.1%).
Valuation It trades at 22.9× forward earnings against a peer median of 23.0× (5th cheapest of 9).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.0 points below its cost of capital (8.0% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.27B | CN¥1.23B | CN¥1.24B | CN¥1.09B | CN¥1.41B |
| Revenue growth | — | 0% | +13% | -23% | — |
| Gross profit | CN¥696M | CN¥641M | CN¥679M | CN¥616M | CN¥895M |
| EBITDA | n/a | CN¥536M | CN¥472M | CN¥303M | CN¥458M |
| Net income | CN¥239M | CN¥305M | CN¥309M | CN¥192M | CN¥384M |
| Free cash flow | CN¥131M | CN¥117M | -CN¥13.3M | -CN¥84.6M | -CN¥1.99M |
| Capital expenditure | CN¥319M | CN¥362M | CN¥480M | CN¥245M | CN¥380M |
| Total debt | CN¥1.88B | CN¥2.03B | CN¥2.11B | CN¥2.11B | CN¥884M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Garden Biopharmaceutical 300401.SZ | $922M | -14% | +2% | 24% | 22.9× | 9.1% |
| DSM-Firmenich DSFIR.AS | $27.5B | +47% | -45% | 8% | 28.6× | 23.7% |
| Zhejiang NHU 002001.SZ | $11.8B | -22% | +11% | 33% | 9.7× | -8.3% |
| Basf BAS.DE | $50.1B | 0% | -4% | 7% | 15.8× | 5.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300401.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.3% | -10.0% | 10th highest of 21 |
| 6-month return | -14.1% | -20.9% | 8th highest of 20 |
| Distance from 52-week high | -50.8% | -46.6% | 9th lowest of 21 |
| Revenue growth (TTM) | +2.4% | +11.3% | 9th lowest of 18 |
| Operating margin | 23.6% | 7.1% | 3rd highest of 18 |
| Forward P/E | 22.9× | 23.0× | 5th cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | 9.1% | 7.7% | 6th most demanding of 12 |
| Growth delivered (Del g) | +13.4% | +4.9% | 4th highest of 12 |
| Hurdle (Req g minus delivered) | -4.3 pp | +2.8 pp | 5th least demanding of 12 |
| ROIC minus cost of capital | -0.0 pp | -2.0 pp | 6th highest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 22.9× | 9.1% | +13.4% |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 50.2× | -10.2% | +18.1% |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 9.8× | -3.7% | +13.8% |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | n/a | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | n/a | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | n/a | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | n/a | 10.3% | -13.7% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | n/a | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | n/a | 7.7% | -6.9% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | n/a | 19.4% | -6.0% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 42.3× | 11.6% | +4.9% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 15.9× | 17.6% | +7.8% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 12.5× | 2.3% | -0.5% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | n/a | -7.6% | -0.7% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |